The largest database of trusted experimental protocols

Hm450k array

Manufactured by Illumina
Sourced in United States

The HM450K array is a microarray-based technology developed by Illumina for genome-wide DNA methylation analysis. The array interrogates over 450,000 CpG sites across the human genome, providing a comprehensive view of DNA methylation patterns.

Automatically generated - may contain errors

9 protocols using hm450k array

1

Integrative Analysis of DNA Methylation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The DNA methylation datasets generated from Illumina HM450K array, EPIC array platform and WGBS were downloaded from the Encyclopedia of DNA Elements (ENCODE) project and GEO Datasets Database (see Additional file 1). We processed the HM450K and RPIC data using the ‘minfi’ Bioconductor package [19 (link)]. Probes were excluded if the detection p-value greater than 0.05. The target CpG sites annotated to the sex chromosomes or common SNPs were removed from subsequent analysis. The methylation level of each site was measured as beta-value which was the ratio of signal compared with the sum of the methylated and unmethylated probes.
The WGBS data of H1-hESC and GM12878 cell lines were performed in two biological replicates. First, we merged the two sets of methylation data by summing the read counts. At each CpG site the methylation level was calculated as the ratio of the counts of methylated reads to total reads. Then MethylSeekR was used to identify the UMRs (unmethylated regions), LMRs (low-methylated regions) and PMDs (partially methylated domains) on the WGBS datasets. The other genomic regions were treated as FMRs. The Pearson correlation coefficients of methylation level between WGBS and HM450K datasets for two cell lines and between EPIC and WGBS datasets for GM12878 cell line were calculated on the common CpG sites for different platform.
+ Open protocol
+ Expand
2

Comparative Analysis of DNA Methylation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The datasets were chosen such that one measured DNAm a brain region distinct from that which we studied previously and the other two measured DNAm in a peripheral tissue. Additional criteria for selecting the datasets for analysis included that they i) were publicly available, ii) measured DNAm using Human Methylation 450K array platform (HM450K Array; Illumina, San Diego, CA, USA), iii) included an age range of at least 30 years for mixed-age samples, and iv) made up of a relatively large number of samples compared to other similar datasets.
+ Open protocol
+ Expand
3

Multiomics Data of Bladder Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
Four types of data were available for these patients: clinical information, the median mRNA levels of gene expression (RNA-seq V2 RSEM normalized expression values), DNA methylation profiles (METH) generated from Illumina HM450K array (beta-values for genes), and protein expression profiling with reverse-phase protein arrays (RPPA). Data was obtained from the Cancer Genome Atlas Urothelial Bladder Carcinoma (TCGA-BLCA) program [33 (link)].
+ Open protocol
+ Expand
4

Epigenetic and Metabolic Markers in Fasting

Check if the same lab product or an alternative is used in the 5 most similar protocols
Our analyses focused on fasting TG as the primary outcome measure. Secondary outcomes included DNA methylation and HDL. Of those with genotype data, 707 participants had whole-genome methylation data measured from CD4+ T cells at visit 2. The HM450K array was used to measure DNA methylation (Illumina, Inc., San Diego, CA, USA) following bisulphite conversion. The platform detects methylation status of 485,577 CpG (cystine-phosphate-guanine) sites by sequencing-based genotyping of bisulphite-treated DNA. The methylation score for each CpG is reported as a β value, ranging from 0 (nonmethylated) to 1 (completely methylated), according to the intensity ratio of detected methylation. We calculated principal components (PCs) using methylation β values across all CpGs in R (v3.3.1) and used the first four PCs to adjust to control for cell purity and batch effects prior to performing association analyses. Covariates included sex, baseline age, and study center. Additionally, we adjusted for baseline smoking status, as had been done in previous genetic and methylation association analyses [12 (link)–15 (link)].
+ Open protocol
+ Expand
5

Epigenome-Wide Analysis of Incident T2D

Check if the same lab product or an alternative is used in the 5 most similar protocols
Apart from identifying potentially novel differentially methylated CpG sites in individuals with incident type 2 diabetes versus those without, we explored how many of the previously identified type 2 diabetes-associated CpG sites were replicated, particularly in Black adults since previous DNAm studies of incident type 2 diabetes did not consider individuals of African descent. We compiled a list of EWAS of both incident and prevalent type 2 diabetes from the NCBI PubMed database by searching the terms “DNA methylation”, “type 2 diabetes” and “epigenome-wide association analysis” or “EWAS” as of July 21, 2023. We included EWAS that used DNAm data measured through the Illumina platform (HM450K array or other variation of the Illumina Methylation array such as 27K, EPIC) as either exposure or outcome based on study design. We shortlisted a total of 17 studies including studies on DNAm from various tissues such as pancreatic islets, liver biopsy, subcutaneous and visceral adipose tissues, and whole blood (Supplementary Table 1).18 (link)–26 (link), 47 (link)–54 Study-specific significance thresholds were used to obtain candidate CpG sites from each study. A total of 18,131 candidate CpG sites (unique candidate CpG sites: 419 from blood, 15,728 from adipose, 287 from liver, and 1,924 from pancreas) were looked up in the results from our primary time-to-event analysis.
+ Open protocol
+ Expand
6

Integrative Methylation Analysis in Breast Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
We performed a combined study using methylation data from Flower et al.36 (link) analysed by Infinium HumanMethylation450 BeadChip and data from the metEPICVal study previously described. First, we analysed HM450K array samples according to the methods described in the data pre-processing section. We retained methylation levels for 405,068 probes present in both metEPICVal and Flower et al.’s36 (link) HM450K study in a total of 64 samples (32 BCO samples, 32 from BCVY) that were used in the validation study.
Additionally, we used methylation data from independent breast tissue samples available from TCGA, that includes data for 485,577 probes in 720 BCO and 27 BCVY samples. Gene expression study for TCGA data was done with 50 permutations, and 50 samples were randomly selected and balanced by subtype.
Both studies were performed using the Illumina HM450K array, which includes only half of the probes present in the EPICarray. To validate our results from the BCVY-BCO study we selected differentially methylated miRNA probes that were included in HM450K and a Wilcoxon Rank Sum test was performed between BCVY and BCO tumour samples.
+ Open protocol
+ Expand
7

Methylation Analysis of SLE-ESRD

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood DNA methylation was interrogated using the Illumina HM450k array. Data acquisition, preprocessing, QC, normalisation of methylation data and estimation of relative blood cell type distribution have been described previously.24 (link) Differential DNA methylation for CpG sites at the loci of interest between SLE-ESRD (n=20) and non-renal SLE (n=302) was tested using a linear regression model including age at sampling, sex, blood cell type distribution and HM450k BeadChip as covariates, with significance defined at p<0.0028 after Bonferroni correction for multiple testing (0.05/18 tests).
+ Open protocol
+ Expand
8

Genome-wide DNA Methylation Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Genome-wide DNA methylation was measured using the HumanMethylation450K (HM450K) BeadChip array (Illumina). For each sample, a total of 300–500 ng of tumour DNA was bisulfite-converted using Zymo Gold EZ-DNA kit (Irvine, CA) and restored using the DNA Restoration Kit as per the manufacturer’s instructions (Illumina, CA, United States). Sample DNA quantity was assessed using an in-house modified quality control protocol [80 (link)]. Samples that passed the final quality check were run on the HM450K array (Illumina) according to manufacturer’s instructions.
+ Open protocol
+ Expand
9

Meta-Analysis of DNA Methylation

Check if the same lab product or an alternative is used in the 5 most similar protocols
We employed a sample-size weighted strategy to combine the p values reported in the included studies, taking into consideration the direction of the association effect size. This strategy was implemented using R software (https://www.r-project.org/). In this meta-analysis the CpG site with p value less than 1.03 × 10−7 (Bonferroni correction based on 485,577 CpGs designed in Illumina HM450K array) and with effect sizes consistent with the direction across all included studies, were considered as significant.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!